Polygenic risk score analyses on embryos (PGT-P) are being marketed by some private testing companies to parents using in vitro fertilisation as being useful in selecting the embryos that carry the least risk of disease in later life. It appears that at least one child has been born after such a procedure. But the utility of a PRS in this respect is severely limited, and to date, no clinical research has been performed to assess its diagnostic effectiveness in embryos. Patients need to be properly informed on the limitations of this use of PRSs, and a societal debate, focused on what would be considered acceptable with regard to the selection of individual traits, should take place before any further implementation of the technique in this population.

Francesca Forzano, 1., Olga Antonova, 2., Angus Clarke, 3., Guido De Wert, 4., Sabine Hentze, 5., Yalda Jamshidi, 6., Yves Moreau, 7., Markus Perola, 8., Inga Prokopenko, 9. 1. 1., Andrew Read, 1., Alexandre Reymond, 1., Vigdis Stefansdottir, 1., Carla Van El, 1., Genuardi, M., 16, 1., Executive Committee Of The European Society Of Human, G., Public And Professional Policy Committee Of The European Society Of Human, G., The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice, <<EUROPEAN JOURNAL OF HUMAN GENETICS>>, 2022; 2022 (5): 493-495. [doi:10.1038/s41431-021-01000-x] [https://hdl.handle.net/10807/219715]

The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice

Genuardi, M.;
2022

Abstract

Polygenic risk score analyses on embryos (PGT-P) are being marketed by some private testing companies to parents using in vitro fertilisation as being useful in selecting the embryos that carry the least risk of disease in later life. It appears that at least one child has been born after such a procedure. But the utility of a PRS in this respect is severely limited, and to date, no clinical research has been performed to assess its diagnostic effectiveness in embryos. Patients need to be properly informed on the limitations of this use of PRSs, and a societal debate, focused on what would be considered acceptable with regard to the selection of individual traits, should take place before any further implementation of the technique in this population.
2022
Inglese
Francesca Forzano, 1., Olga Antonova, 2., Angus Clarke, 3., Guido De Wert, 4., Sabine Hentze, 5., Yalda Jamshidi, 6., Yves Moreau, 7., Markus Perola, 8., Inga Prokopenko, 9. 1. 1., Andrew Read, 1., Alexandre Reymond, 1., Vigdis Stefansdottir, 1., Carla Van El, 1., Genuardi, M., 16, 1., Executive Committee Of The European Society Of Human, G., Public And Professional Policy Committee Of The European Society Of Human, G., The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice, <<EUROPEAN JOURNAL OF HUMAN GENETICS>>, 2022; 2022 (5): 493-495. [doi:10.1038/s41431-021-01000-x] [https://hdl.handle.net/10807/219715]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/219715
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact